Visión generalGráficoNoticiasTraderScreen

Morgan Stanley Call 625 LONN 20.1.../  DE000MG2UMF5  /

Stuttgart
08/11/2024  15:47:11 Diferencia+0.003 Bid22:00:39 Ask22:00:39 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
0.034EUR +9.68% -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 LONZA N 625.00 CHF 20/12/2024 Call
GlobeNewswire 26/08 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire 23/08 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire 08/08 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 06/08 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 14/06 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire 13/06 Repligen Announces CEO Transition Plan
GlobeNewswire 30/05 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire 15/05 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire 08/05 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/05 Maravai LifeSciences Reports First Quarter 2024 Financial Results
GlobeNewswire 04/04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire 04/04 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire 27/02 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire 15/02 Galapagos presents at EBMT-EHA annual meeting 2024
GlobeNewswire 04/01 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire 19/12/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire 09/12/2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire 07/12/2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire 07/12/2023 Business Update
GlobeNewswire 06/11/2023 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 01/11/2023 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO
GlobeNewswire 19/10/2023 Viralgen welcomes back Andy Holt as CCO
GlobeNewswire 16/10/2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire 02/10/2023 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire 20/09/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023